- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
3M Hires Bryan Hanson as Health Care Business Group CEO
Executive to join company on September 1.
After serving as CEO for Zimmer Biomet since 2017, Bryan Hanson has been appointed as the new CEO of 3M’s Health Care Business Group. Expected to take the reins when the independent health care company is spun off from 3M, Hanson will officially join the organization on September 1.
As a separate entity, 3M believes that Health Care Business Group will be better positioned to deliver industry-leading innovation that enables better, smarter, and safer healthcare for patients worldwide.
“We are pleased to have Bryan join us to advance the spin-off of our Health Care business and build a leading independent medical technology innovation company,” said Mike Roman, 3M chairman, CEO. “His industry expertise, ability to drive growth, and track record of building a strong culture and teams will make an immediate impact.”
Reference: Bryan Hanson Named CEO of 3M’s Health Care Business Group. 3M. August 22, 2023. Accessed August 23, 2023. https://news.3m.com/Bryan-Hanson-Named-CEO-of-3Ms-Health-Care-Business-Group
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
